ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
NY Times Magazine Examines HIV/AIDS Experimental Treatment Tenofovir PrEP
Researchers have made progress in treating people already living with HIV/AIDS, but when it comes to preventing the virus' spread, "success is spotty," the New York Times Magazine reports. "Intrigued by the prospects" of preventing HIV transmission among high-risk groups, researchers have launched several clinical trials to test the efficacy of pre-exposure prophylaxis. The trials all utilize the antiretroviral tenofovir because it appears "safer" than other HIV/AIDS medications currently available. "Optimistic mathematical models show that if tenofovir PrEP is effective 90% of the time and is used by 90% of the people who are at the highest risk of becoming infected, it could cut new HIV infections in a community by more than 80% in a few years." Regardless of tenofovir PrEP's effectiveness, it "will not substitute for an AIDS vaccine," the Times reports, noting, "Then again, no AIDS vaccine is on the near horizon" (Cohen, New York Times, 1/22).
"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
NY Times, revista analizeazã HIV / SIDA tratament experimental PReP de fumarat de tenofovir - NY Times Magazine Examines HIV/AIDS Experimental Treatment Tenofovir PrEP - articole medicale engleza - startsanatate
